• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.作者更正：利妥昔单抗治疗滤泡性淋巴瘤：2期TRANSCEND FL研究
Nat Med. 2024 Aug;30(8):2374. doi: 10.1038/s41591-024-03175-4.
2
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.利妥昔单抗注射用兰尼单抗二线治疗既往未接受造血干细胞移植的复发或难治性大 B 细胞淋巴瘤成人患者（PILOT）：一项开放标签、2 期研究。
Lancet Oncol. 2022 Aug;23(8):1066-1077. doi: 10.1016/S1470-2045(22)00339-4. Epub 2022 Jul 12.
3
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.利妥昔单抗奥滨尤妥珠单抗治疗滤泡性淋巴瘤：2 期 TRANSCEND FL 研究。
Nat Med. 2024 Aug;30(8):2199-2207. doi: 10.1038/s41591-024-02986-9. Epub 2024 Jun 3.
4
Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.利妥昔单抗注射用冻干粉治疗复发或难治性大 B 细胞淋巴瘤。
Future Oncol. 2023 Jan;19(1):19-28. doi: 10.2217/fon-2022-0774. Epub 2023 Jan 18.
5
Lisocabtagene Maraleucel for the treatment of B-cell lymphoma.利妥昔单抗注射用冻干粉治疗 B 细胞淋巴瘤。
Expert Opin Biol Ther. 2021 Sep;21(9):1151-1156. doi: 10.1080/14712598.2021.1933939. Epub 2021 Jun 28.
6
Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison.替沙格赛基因治疗和利索卡提基因治疗在复发/难治性大B细胞淋巴瘤成人患者中的疗效比较：间接治疗比较
Leuk Lymphoma. 2022 Apr;63(4):845-854. doi: 10.1080/10428194.2021.2010069. Epub 2022 Jan 2.
7
Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials.接受 lisocabtagene maraleucel 三线或以上治疗的复发/难治性大 B 细胞淋巴瘤患者的输注后监测费用，按治疗地点分析，TRANSEND NHL 001 和 OUTREACH 试验。
Leuk Lymphoma. 2021 Sep;62(9):2169-2176. doi: 10.1080/10428194.2021.1910686. Epub 2021 May 21.
8
[New drug approval: Lisocabtagene maraleucel for patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma or follicular lymphoma grade 3B after two or more lines of systemic treatment].[新药获批：利妥昔单抗用于经两种或更多线全身治疗后复发或难治性弥漫性大B细胞淋巴瘤、原发性纵隔B细胞淋巴瘤或3B级滤泡性淋巴瘤患者]
Bull Cancer. 2022 Sep;109(9):879-880. doi: 10.1016/j.bulcan.2022.04.020. Epub 2022 Jun 15.
9
Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL桥接化疗：滤泡性淋巴瘤、套细胞淋巴瘤和慢性淋巴细胞白血病
10
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel.嵌合抗原受体T细胞疗法用于复发或难治性大B细胞淋巴瘤三线及后续治疗的匹配调整间接治疗比较：利妥昔单抗与替沙格赛定。
Exp Hematol Oncol. 2022 Mar 25;11(1):17. doi: 10.1186/s40164-022-00268-z.

引用本文的文献

1
Comparative Analysis of Bispecific Antibodies and CAR T-Cell Therapy in Follicular Lymphoma.滤泡性淋巴瘤中双特异性抗体与嵌合抗原受体T细胞疗法的比较分析
Eur J Haematol. 2025 Jan;114(1):4-16. doi: 10.1111/ejh.14335. Epub 2024 Oct 27.
2
Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial.马吉妥昔单抗联合利妥昔单抗治疗复发/难治性惰性非霍奇金淋巴瘤：一项 1/2 期试验的 3 年随访结果。
Blood Adv. 2024 Nov 26;8(22):5855-5863. doi: 10.1182/bloodadvances.2024013277.
3
Promising outcomes with liso-cel in patients with R/R follicular lymphoma.利妥昔单抗治疗复发/难治性滤泡性淋巴瘤患者的疗效显著。
Nat Rev Clin Oncol. 2024 Sep;21(9):639. doi: 10.1038/s41571-024-00920-z.

Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.

作者信息

Morschhauser Franck, Dahiya Saurabh, Palomba M Lia, Martin Garcia-Sancho Alejandro, Reguera Ortega Juan Luis, Kuruvilla John, Jäger Ulrich, Cartron Guillaume, Izutsu Koji, Dreyling Martin, Kahl Brad, Ghesquieres Hervé, Ardeshna Kirit, Goto Hideki, Barbui Anna Maria, Abramson Jeremy S, Borchmann Peter, Fleury Isabelle, Mielke Stephan, Skarbnik Alan, de Vos Sven, Kamdar Manali, Karmali Reem, Viardot Andreas, Farazi Thalia, Fasan Omotayo, Lymp James, Vedal Min, Nishii Rina, Avilion Ariel, Papuga Jessica, Kumar Jinender, Nastoupil Loretta J

机构信息

Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.

Stanford University School of Medicine, Stanford, CA, USA.

出版信息

Nat Med. 2024 Aug;30(8):2374. doi: 10.1038/s41591-024-03175-4.

DOI:10.1038/s41591-024-03175-4
PMID:38982297
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11333276/
Abstract
摘要